KR100190729B1 - 구토증 치료약제 - Google Patents

구토증 치료약제 Download PDF

Info

Publication number
KR100190729B1
KR100190729B1 KR1019940012527A KR19940012527A KR100190729B1 KR 100190729 B1 KR100190729 B1 KR 100190729B1 KR 1019940012527 A KR1019940012527 A KR 1019940012527A KR 19940012527 A KR19940012527 A KR 19940012527A KR 100190729 B1 KR100190729 B1 KR 100190729B1
Authority
KR
South Korea
Prior art keywords
phenylpiperidine
alkyl
phenyl
methoxybenzylamino
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940012527A
Other languages
English (en)
Korean (ko)
Other versions
KR950000144A (ko
Inventor
마노즈씨.데사이
죤에이.로위3세
죤더블유.와트슨
Original Assignee
디. 제이. 우드, 스피겔 알렌 제이
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디. 제이. 우드, 스피겔 알렌 제이, 화이자 인코포레이티드 filed Critical 디. 제이. 우드, 스피겔 알렌 제이
Publication of KR950000144A publication Critical patent/KR950000144A/ko
Application granted granted Critical
Publication of KR100190729B1 publication Critical patent/KR100190729B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
KR1019940012527A 1993-06-04 1994-06-03 구토증 치료약제 Expired - Fee Related KR100190729B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8/072,629 1993-06-04
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis
US8/072.629 1993-06-04

Publications (2)

Publication Number Publication Date
KR950000144A KR950000144A (ko) 1995-01-03
KR100190729B1 true KR100190729B1 (ko) 1999-06-01

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940012527A Expired - Fee Related KR100190729B1 (ko) 1993-06-04 1994-06-03 구토증 치료약제

Country Status (19)

Country Link
US (1) US5393762A (cg-RX-API-DMAC10.html)
EP (1) EP0627221B1 (cg-RX-API-DMAC10.html)
JP (1) JP2671972B2 (cg-RX-API-DMAC10.html)
KR (1) KR100190729B1 (cg-RX-API-DMAC10.html)
CN (1) CN1100535C (cg-RX-API-DMAC10.html)
AT (1) ATE209490T1 (cg-RX-API-DMAC10.html)
AU (1) AU666077B2 (cg-RX-API-DMAC10.html)
CA (1) CA2124990C (cg-RX-API-DMAC10.html)
DE (1) DE69429208T2 (cg-RX-API-DMAC10.html)
DK (1) DK0627221T3 (cg-RX-API-DMAC10.html)
ES (1) ES2164088T3 (cg-RX-API-DMAC10.html)
HU (1) HU222243B1 (cg-RX-API-DMAC10.html)
IL (1) IL109802A (cg-RX-API-DMAC10.html)
MY (1) MY115310A (cg-RX-API-DMAC10.html)
NZ (1) NZ260674A (cg-RX-API-DMAC10.html)
PT (1) PT627221E (cg-RX-API-DMAC10.html)
RU (1) RU2135179C1 (cg-RX-API-DMAC10.html)
TW (1) TW318791B (cg-RX-API-DMAC10.html)
ZA (1) ZA943896B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DE69617226T2 (de) * 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co., Inc. Piperidinderivate.
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
AU736542B2 (en) * 1997-06-27 2001-08-02 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
EP1145714A4 (en) * 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd DRUGS
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
RU2197961C2 (ru) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Средство для профилактики и купирования тошноты и рвоты
RU2183118C1 (ru) * 2001-07-12 2002-06-10 Государственный научный центр РФ Институт медико-биологических проблем РАН Способ профилактики вестибуловегетативных расстройств у человека в условиях воздействий, вызывающих укачивание
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
BRPI0507325A (pt) * 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド 3―アミノ―2―アリールキヌクリジン
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
ATE121389T1 (de) * 1990-09-28 1995-05-15 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
CA2100163A1 (en) * 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
DE69200921T2 (de) * 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (cg-RX-API-DMAC10.html) * 1991-06-21 1993-03-21 Pfizer
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0607164B1 (en) * 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
ES2111650T3 (es) * 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
ES2147759T3 (es) * 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
AU5776099A (en) * 1998-08-14 2000-03-06 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
US5393762A (en) 1995-02-28
DK0627221T3 (da) 2002-02-11
IL109802A (en) 2002-04-21
CA2124990C (en) 1999-04-20
KR950000144A (ko) 1995-01-03
DE69429208T2 (de) 2002-05-23
JPH0753362A (ja) 1995-02-28
PT627221E (pt) 2002-04-29
TW318791B (cg-RX-API-DMAC10.html) 1997-11-01
AU6452194A (en) 1994-12-15
ZA943896B (en) 1995-12-04
RU94020410A (ru) 1996-05-10
HU9401676D0 (en) 1994-09-28
CN1121806A (zh) 1996-05-08
HU222243B1 (hu) 2003-05-28
JP2671972B2 (ja) 1997-11-05
NZ260674A (en) 2000-07-28
AU666077B2 (en) 1996-01-25
HUT71550A (en) 1995-12-28
ES2164088T3 (es) 2002-02-16
IL109802A0 (en) 1994-08-26
EP0627221A3 (en) 1995-08-02
RU2135179C1 (ru) 1999-08-27
EP0627221B1 (en) 2001-11-28
DE69429208D1 (de) 2002-01-10
EP0627221A2 (en) 1994-12-07
CN1100535C (zh) 2003-02-05
ATE209490T1 (de) 2001-12-15
MY115310A (en) 2003-05-31

Similar Documents

Publication Publication Date Title
US5393762A (en) Pharmaceutical agents for treatment of emesis
DE69318854T2 (de) Spiroazacyclischderivate als substanz p antagonisten
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
SK12793A3 (en) Heterocyclic compounds, process for their preparation and their using
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
WO1993019064A1 (en) Quinuclidine derivatives as substance p antagonists
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
TW201632522A (zh) 針對疼痛具有多模式活性的螺-異喹啉-1,4’-哌啶化合物
ES2250345T3 (es) Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico.
US20070099956A1 (en) Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl
US5750535A (en) Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5990125A (en) NK-1 receptor antagonists for the treatment of cancer
EP0721778B1 (en) NK-1 receptor antagonists for the treatment of neuronal injury and stroke
AU700520B2 (en) NK-1 receptor antagonists for the treatment of cancer
EP0659409A2 (en) Substance 1 antagonists for the inhibition of angiogenesis
IE63194B1 (en) Antiemesis ergoline derivatives
US4904673A (en) Agent for treating bradycardia and bradyarrhythmia
EP0790825A1 (en) Nk-1 receptor antagonists for the treatment of eye disorders
KR19980080824A (ko) 지연성 구토 치료를 위한 nk-1 수용체 길항제

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20080103

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090122

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000